149 related articles for article (PubMed ID: 24286402)
1. miR-30b and miR-30c expression predicted response to tyrosine kinase inhibitors as first line treatment in non-small cell lung cancer.
Gu YF; Zhang H; Su D; Mo ML; Song P; Zhang F; Zhang SC
Chin Med J (Engl); 2013 Dec; 126(23):4435-9. PubMed ID: 24286402
[TBL] [Abstract][Full Text] [Related]
2. Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patients.
Hojbjerg JA; Ebert EBF; Clement MS; Winther-Larsen A; Meldgaard P; Sorensen B
Lung Cancer; 2019 Sep; 135():92-96. PubMed ID: 31447008
[TBL] [Abstract][Full Text] [Related]
3. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers.
Garofalo M; Romano G; Di Leva G; Nuovo G; Jeon YJ; Ngankeu A; Sun J; Lovat F; Alder H; Condorelli G; Engelman JA; Ono M; Rho JK; Cascione L; Volinia S; Nephew KP; Croce CM
Nat Med; 2011 Dec; 18(1):74-82. PubMed ID: 22157681
[TBL] [Abstract][Full Text] [Related]
4. microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation.
Shen Y; Tang D; Yao R; Wang M; Wang Y; Yao Y; Li X; Zhang H
Med Oncol; 2013 Dec; 30(4):750. PubMed ID: 24198203
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-30b inhibits non-small cell lung cancer cell growth by targeting the epidermal growth factor receptor.
Qi Z; Zhang B; Zhang J; Hu Q; Xu F; Chen B; Zhu C
Neoplasma; 2018; 65(2):192-200. PubMed ID: 29534579
[TBL] [Abstract][Full Text] [Related]
6. miR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type.
Li J; Li X; Ren S; Chen X; Zhang Y; Zhou F; Zhao M; Zhao C; Chen X; Cheng N; Zhao Y; Zhou C; Hirsch FR
Oncotarget; 2014 Sep; 5(17):7902-16. PubMed ID: 25277203
[TBL] [Abstract][Full Text] [Related]
7. miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
Ge P; Cao L; Chen X; Jing R; Yue W
BMC Cancer; 2019 Dec; 19(1):1203. PubMed ID: 31823748
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
9. MiR-130a overcomes gefitinib resistance by targeting met in non-small cell lung cancer cell lines.
Zhou YM; Liu J; Sun W
Asian Pac J Cancer Prev; 2014; 15(3):1391-6. PubMed ID: 24606471
[TBL] [Abstract][Full Text] [Related]
10. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
11. miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
Gao Y; Fan X; Li W; Ping W; Deng Y; Fu X
Biochem Biophys Res Commun; 2014 Mar; 446(1):179-86. PubMed ID: 24582749
[TBL] [Abstract][Full Text] [Related]
12. Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan.
Chang CH; Lee CH; Ko JC; Chang LY; Lee MC; Wang JY; Yu CJ
Cancer Med; 2017 Jul; 6(7):1563-1572. PubMed ID: 28639751
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-30b/c inhibits non-small cell lung cancer cell proliferation by targeting Rab18.
Zhong K; Chen K; Han L; Li B
BMC Cancer; 2014 Sep; 14():703. PubMed ID: 25249344
[TBL] [Abstract][Full Text] [Related]
14. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
Wang HY; Liu YN; Wu SG; Hsu CL; Chang TH; Tsai MF; Lin YT; Shih JY
Cancer Biomark; 2020; 28(3):351-363. PubMed ID: 32417760
[TBL] [Abstract][Full Text] [Related]
15. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
16. Serum miR-30c Level Predicted Cardiotoxicity in Non-small Cell Lung Cancer Patients Treated with Bevacizumab.
Zhou F; Lu X; Zhang X
Cardiovasc Toxicol; 2018 Jun; 18(3):284-289. PubMed ID: 29737469
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.
Cho KM; Keam B; Kim TM; Lee SH; Kim DW; Heo DS
Korean J Intern Med; 2015 Nov; 30(6):891-8. PubMed ID: 26552465
[TBL] [Abstract][Full Text] [Related]
18. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
Lee JK; Shin JY; Kim S; Lee S; Park C; Kim JY; Koh Y; Keam B; Min HS; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS; Lee SH; Kim JI
Ann Oncol; 2013 Aug; 24(8):2080-7. PubMed ID: 23559152
[TBL] [Abstract][Full Text] [Related]
19. Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations.
Wang F; Diao XY; Zhang X; Shao Q; Feng YF; An X; Wang HY
Cancer Commun (Lond); 2019 Mar; 39(1):7. PubMed ID: 30823937
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
Aiko N; Shimokawa T; Miyazaki K; Misumi Y; Agemi Y; Ishii M; Nakamura Y; Yamanaka T; Okamoto H
BMC Cancer; 2018 Oct; 18(1):1012. PubMed ID: 30348116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
